Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trial

Marnie Newell,Lynne Postovit,Karen King,Anil A Joy ,John R Mackey ,Vera C Mazurak ,Sanraj Basi ,Judith Meza–Junco ,Weifeng Dong ,M Álvarez-Camacho ,Kerry S Courneya ,George O Wood ,Ann Chisotti,Richard Berendt,Gilbert Bigras,Susan Goruk,Kristi Baker,Deborah Miede,Alison Schmidt,Sunita Ghosh,Xiaofu Zhu

doi:10.1136/bmjopen-2019-030502

Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trial

Marnie Newell, Lynne Postovit + Show 19 more

Open Access

https://doi.org/10.1136/bmjopen-2019-030502

Copy DOI

Journal: BMJ Open	Publication Date: Sep 1, 2019
Citations: 15	License type: open-access

Affiliation: Alberta Health Services, University of Alberta

#Docosahexaenoic Acid #Rate Of pCR In Breast + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

IntroductionNeoadjuvant chemotherapy for breast cancer treatment is prescribed to facilitate surgery and provide confirmation of drug-sensitive disease, and the achievement of pathological complete response (pCR) predicts improved long-term outcomes. Docosahexaenoic...

Full Text